The reoccurrence of fever on aspirin during recovery from Kawasaki disease should be considered a resurgence of Kawasaki disease after all other factors have been excluded from causing the fever, and will require re-treatment with intravenous immunoglobulin. In some patients with Kawasaki disease whose fever persists or recurs after treatment with intravenous immunoglobulin and aspirin, a single immunoglobulin infusion is needed for remedial treatment. For patients with refractory Kawasaki disease whose fever is not completely controlled even with multiple immunoglobulin infusions, glucocorticosteroids, and anti-TNF-alpha medications (e.g., infliximab and etanercept, etc.) need to be added to the regimen. Patients with Kawasaki disease presenting with recurrent fever are at high risk for coronary artery anomalies and long-term sequelae, and remedies generally do not always achieve the desired therapeutic effect; ideally, such patients should be prospectively identified before coronary artery anomalies occur, so that complementary therapies can be initiated to prevent or mitigate vascular damage. In conclusion, the patient’s temperature should be closely monitored during the treatment phase and for a long time during the recovery period, as well as regular review of the cardiac and coronary vasculature, and prompt intervention if any abnormality occurs.